Q2 FY2026 · ended Jun 30, 2026 · Revenue $19.94M, +15.9% YoY · Filed Aug 4, 2026
Exagen Inc. (XGN) files with the SEC under industry code 8071, Services-Medical Laboratories. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $19.9 million and a net loss of $3.2 million. Free cash flow was $3.4 million. As of Jun 30, 2026 it held $24.6 million in cash and investments and $27.7 million in total debt.
Revenue
$19.94M
+15.9% vs year-ago quarter
Net income
$-3.20M
+28.0% vs year-ago quarter
Operating cash flow
$3.99M
+238.2% vs year-ago quarter
Free cash flow
$3.44M
+211.3% vs year-ago quarter
EPS
$-0.13
+38.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
24.23M
+10.1% vs year-ago quarter
Net cash
$-3.07M
Q2 FY2026
Operating margin
-18.6%
TTM
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- XGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Vista, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1274737
- Former names
- EXAGEN DIAGNOSTICS INC (until May 18, 2017)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $19.9M | $17.3M | $16.6M | $17.2M | $17.2M |
| Operating income | -$1.7M | -$3.4M | -$5.0M | -$3.1M | -$2.6M |
| Net income | -$3.2M | -$4.0M | -$4.7M | -$7.1M | -$4.4M |
| Diluted EPS | -$0.13 | -$0.17 | -$0.20 | -$0.31 | -$0.21 |
| Operating cash flow | $4.0M | -$10.4M | -$3.0M | $2.9M | -$2.9M |
| Free cash flow | $3.4M | -$10.6M | -$3.1M | $2.7M | -$3.1M |
| Total assets | $51.9M | $52.0M | $58.0M | $62.8M | $58.8M |
| Total liabilities | $39.7M | $37.5M | $40.6M | $44.7M | $37.7M |
| Stockholders' equity | $12.2M | $14.4M | $17.4M | $18.1M | $21.0M |
| Cash and investments | $24.6M | $21.5M | $32.2M | $35.7M | $30.0M |
| Total debt | $27.7M | $27.1M | $27.7M | $27.8M | $25.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2026 | Jun 9, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 11, 2026 | May 11, 2026 |
| ARS | Annual report to shareholders | Apr 27, 2026 | Dec 31, 2025 |
All 421 Exagen Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.